Memory enhancing and neuroprotective effects of apomorphine in a rat model of dementia.
AChE
Apomorphine
Biogenic amines
Catalase
Glutathione peroxidise
Lipid peroxidation
Morris water maze
Scopolamine
Superoxide dismutase
Journal
Metabolic brain disease
ISSN: 1573-7365
Titre abrégé: Metab Brain Dis
Pays: United States
ID NLM: 8610370
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
received:
29
08
2023
accepted:
10
06
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
Oxidative stress from generation of increased reactive oxygen species or has been reported to play an important role in dementia. Oxidative stress due to free radicals of oxygen or reactive oxygen species could be precipitating factors in the etiology of dementia. Apomorphine has been reported to have neuroprotective effects. To monitor memory enhancing and neuroprotective effects of apomorphine, we determined the antioxidant enzymes activities, lipid peroxidation, acetylcholine esterase (AChE) activity in brain and plasma, following repetitive administration of apomorphine in rat model of dementia. Biogenic amine levels were also monitored in hippocampus. Repeated administration of scopolamine was taken as an animal model of dementia. Decreased glutathione peroxidase, superoxide dismutase and catalase activities were observed in these animal models of dementia. While increased lipid peroxidation was also observed in the brain and plasma samples. The results showed significant effects of apomorphine. The activities of antioxidant enzymes displayed increased activities in both brain and plasma. Glutathione peroxidase and catalase activities were found to be significantly higher in brain and plasma of apomorphine treated rats. Superoxide dismutase (SOD) was significantly decreased in plasma of scopolamine injected rats; and a decreased tendency (non-significant) of SOD in brain was also observed. AChE activity in brain and plasma was significantly decreased in scopolamine treated rats. Learning and memory of rats in the present study was assessed by Morris Water Maze (MWM). Short-term memory and long-term memory was impaired significantly in scopolamine treated rats, which was prevented by apomorphine. Moreover, a marked decrease in biogenic amines was also found in the brain of scopolamine treated rats and was reverted in apomorphine treated rats. Results showed that scopolamine-treatment induced memory impairment and induced oxidative stress in rats as compared to saline-treated controls. These impairments were significantly restored by apomorphine administration. In conclusion, our data suggests that apomorphine at the dose of 1 mg/kg could be a potential therapeutic agent to treat dementia and related disorders.
Identifiants
pubmed: 38896206
doi: 10.1007/s11011-024-01372-1
pii: 10.1007/s11011-024-01372-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Abdulrahman H, Fletcher PC, Bullmore E, Morcome AM (2017) Dopamine and memory dedifferentiation in aging. Neuroimage 153:211–220
doi: 10.1016/j.neuroimage.2015.03.031
Badshah H, Kim TH, Kim MJ, Ahmad A, Kim MO (2014) Apomorphine attenuates ethanol-induced neurodegeneration in the adult rat cortex. Neurochem Int 74:8–15
doi: 10.1016/j.neuint.2014.04.009
Borgemeester RWK, Van Laar T (2017) Continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with cognitive dysfunction: a retrospective long-term follow-up study. Parkinsonism Relat Disord 45:33–38
doi: 10.1016/j.parkreldis.2017.09.025
Bradley-Whitman MA, Lovell MA (2015) Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update. Arch Toxicol 89:1035–1044
doi: 10.1007/s00204-015-1517-6
Burruss JW, Hurley RA, Taber KH, Rauch RA, Norton RE, Hayman LA (2000) Functional neuroanatomy of the frontal lobe circuits. Radiology 214:227–230
doi: 10.1148/radiology.214.1.r00ja43227
Castri P, Busceti C, Battaglia G, Girardi F, Cavallari M, Orzi F, Fornai F (2006) Protection by apomorphine in two independent models of acute inhibition of oxidative metabolism in rodents. Clin Exp Hypertens 28:387–394
doi: 10.1080/10641960600549827
Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Collin F (2018) Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol 14:450–464
doi: 10.1016/j.redox.2017.10.014
Chidambara-Murthy KN, Jayaprakasha GK, Singh RP (2002) Studies on antioxidant activity of pomegranate (Punica granatum) peel extract using in vivo models. J Agric Food Chem 50:4791–4795
doi: 10.1021/jf0255735
Chow CK, Tappel AL (1971) An enzymatic protective mechanism against lipid peroxidation damage to lungs of ozone-exposed rats. Lipids 7:518–524
doi: 10.1007/BF02533017
de Mello Bastos JM, Dias FR, Alves VH, Carey RJ, Carrera MP (2014) Drug memory substitution during re-consolidation: a single inhibitory autoreceptor apomorphine treatment given during psychostimulant memory re-consolidation replaces psychostimulant conditioning with conditioned inhibition and reverses psychostimulant sensitization. Behav Brain Res 260:139–147
doi: 10.1016/j.bbr.2013.11.004
Deshmukh R, Kaundal M, Bansal V, Samardeep, (2016) Caffeic acid attenuates oxidative stress, learning and memory deficit in intra-cerebroventricular streptozotocin induced experimental dementia in rats. Biomed Pharmacother 81:56–62
doi: 10.1016/j.biopha.2016.03.017
Ellman GL, Courtney KD, AndresV FRM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95
doi: 10.1016/0006-2952(61)90145-9
Flatt JD, Gilsanz P, Quesenberry CP, Albers KB, Whitmer RA (2018) Post-traumatic stress disorder and risk of dementia among members of a health care delivery system. Alz Dem 14:28–34
Flohe L, Gunzler WA (1984) Assays of glutathione peroxidase. Methods Enzymol 105:114–121
Fornai F, Battaglia G, Gesi M, Orzi F, Ruggieri S (2001) Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res 898:27–35
doi: 10.1016/S0006-8993(01)02125-4
Grunblatt E, Mandel S, Maor G, Youdim MB (2001) Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J Neurochem 77:146–156
Guadagno NA, Moriconi C, Licursi V, D’Acunto E, Nisi PS, Carucci N, De Jaco A, Cacci E, Negria R, Lupod G, Mirandaae E (2017) Neuroserpin polymers cause oxidative stress in a neuronal model of the dementia FENIB. Neurobiol Dis 103:32–44
Hanaki M, Murakami K, Katayama S, Akagi K-I, Irie K (2018) Mechanistic analyses of the suppression of amyloid β42 aggregation by apomorphine. Bioorg Med Chem. https://doi.org/10.1016/j.bmc.2018.01.028
doi: 10.1016/j.bmc.2018.01.028
Hartl D, Schuldt V, Forler S, Zabel C, Klose J, Rohe M (2012) Presymptomatic alterations in energy metabolism and oxidative stress in the APP23 mouse model of Alzheimer disease. J Prot Res 11:3295–3304
doi: 10.1021/pr300021e
Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, Motomura K, Soejima N, Yamasaki R, Hashimoto T, Tabira T, LaFerla FM, Kira J (2011) Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann Neurol 69:248–256
doi: 10.1002/ana.22319
Ikram H, Zakir R, Haleem DJ (2011) Effects of single administration of apomorphine on memory and monoamine metabolism: a dose related study. Pak J Pharm Sci 31:439–445
Ikram H, Zakir R, Haleem DJ (2018) Effects of single administration of apomorphine on memory and monoamine metabolism: a dose related study. Pak J Pharm Sci 31(2):439–445
Ikram H, Tasneem S, Perveen S, Zakir R, Haleem DJ (2021) Neurochemical and behavioral effects of fluoxetine on midazolam induce dependence in an animal model of addiction. Pak J Pharm Sci 34(5):1749–1757
Ikram H, Masood R, Syed S, Haleem DJ (2023) Neuropharmacological studies on repurposed utilization of pioglitazone in learning and memory: a dose related study. Pak J Pharm Sci 36(4):1159–1167
Ikram H, Haleem DJ (2019) Repeated treatment with a low dose of reserpine as a progressive model of Parkinson’s dementia. Pak J Pharm Sci (Impact Factor: 0.95) 32(2):555–562
Jung JH, An K, Kwon OB, Kim H, Kim J-H (2011) Pathway-specific alteration of synaptic plasticity in Tg2576 mice. Mol Cells 32:197–201
doi: 10.1007/s10059-011-0077-8
Kumar A, Singh N (2017) Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer’s type. Biomed Pharmacoth 88:698–707
doi: 10.1016/j.biopha.2017.01.059
Li R, Singh M (2014) Sex differences in cognitive impairment and Alzheimer’s disease. Front Neuroendocrinol 35:385–403
doi: 10.1016/j.yfrne.2014.01.002
Lisman JE, Grace AA (2005) The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 46:703–713
doi: 10.1016/j.neuron.2005.05.002
Morelira PI, Smith MA, Zhu X, Santos MS, Oliveira CR, Perry G (2004) Therapeutic potential of oxidant mechanisms in Alzheimer’s disease. Expert Rev Neurother 4:995–1004
doi: 10.1586/14737175.4.6.995
Murakami K, Murata N, Noda Y, Tahara S, Kaneko T, Kinoshita N, Hatsuta H, Murayama S, Barnham KJ, Irie K, Shirasawa T, Shimizu T (2011) OD1 (Copper/Zinc Superoxide Dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of alzheimer disease. J Biol Chem 286:44557–44568
doi: 10.1074/jbc.M111.279208
Neugroschl J, Wang S (2011) Alzheimer’s disease: diagnosis and treatment across the spectrum of disease severity. Mt Sinai J Med 78:596–612
doi: 10.1002/msj.20279
Nobili A, Latagliata EC, Viscomi MT, Cavallucci V, Cutuli D, Giacovazzo G, Krashia P, Rizzo FR, Marino R, Federici M, De Bartolo P, Aversa D, Dell’Acqua MC, Cordella A, Sancandi M, Keller F, Petrosini L, Puglisi-Allegra S, Mercuri NB, Coccurello R, Berretta N, D’Amelio M (2017) Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer’s disease. Nature Comm. https://doi.org/10.1038/ncomms14727
doi: 10.1038/ncomms14727
Pinheiro M, Carey RJ, Cruz Dias FR, de Mattos LW (2012) Memory re-consolidation and drug conditioning: an apomorphine conditioned locomotor stimulant response can be enhanced or reversed by a single high versus low apomorphine post-trial treatment. Psychopharmacology 220:281–291
doi: 10.1007/s00213-011-2474-2
Riedel G, Kang SH, Choi DY, Platt B (2009) Scopolamine-induced deficits in social memory in mice: reversal by donepezil. Behav Brain Res 204:217–225
doi: 10.1016/j.bbr.2009.06.012
Rosa-Grilo M, Qamar MA, As E, Chaudhuri KR (2016) The efficacy of apomorphine – a non-motor perspective. Park Rel Disord 33:28–35
doi: 10.1016/j.parkreldis.2016.11.020
Sandhir R, Yadav A, Sunkaria A, Singhal N (2015). Nano-antioxidants: An emerging strategy for intervention against neurodegenerative conditions. Neurochem Int 89(1): 209–226
Shi Z, Xiao S, Li X (016) Treatment resistant depression or dementia: a case report. Shanghai Arch Psychiatry 28:109–114
Sinha AK (1972) Colorimetric assay of catalase. Anal Biochem 47:389–394
doi: 10.1016/0003-2697(72)90132-7
Titova N, Chaudhuri KR (2016) Apomorphine therapy in Parkinson’s disease and future directions. Park Rel Disord 33:56–60
doi: 10.1016/j.parkreldis.2016.11.013
Vural H, Demirin H, Kara Y, Eren I, Delibas N (2010) Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer’s disease. J Trace Elem Med Biol 24:169–173
doi: 10.1016/j.jtemb.2010.02.002
Yamasaki M, Takeuchi T (2017) Locus Coeruleus and dopamine-dependent memory consolidation. Neural Plast 2017:8602690. https://doi.org/10.1155/2017/8602690
doi: 10.1155/2017/8602690
Yarnall AJ, Lashley T, Ling H, Lees AJ, Coleman SY, O’Sullivan SS, Compta Y, Revesz T, Burn DJ (2016) Apomorphine: a potential modifier of amyloid deposition in Parkinson’s disease? Mov Disord 31:668–675
doi: 10.1002/mds.26422
Yuan H, Sarre S, Ebinger G, Michotte Y (2004) Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson’s disease. Brain Res 1026:95–107
doi: 10.1016/j.brainres.2004.08.015